From our eight offices in Columbus, Cleveland, Cincinnati and Dayton, Ohio; Chicago, IL; Pittsburgh, Pa.; Naples, FL; and Washington, D.C., Porter…
Porter Wright Morris & Arthur LLP | USA | 2 Apr 2019
Much has been written about the European General Data Protection Regulation (GDPR). Commentators have touted the EU’s supposedly superior data…
Porter Wright Morris & Arthur LLP | USA | 25 Aug 2017
Several trade associations for the banking industry have weighed in on a pending potential landmark case in the Northern District of Illinois…
Porter Wright Morris & Arthur LLP | USA | 24 Jan 2014
Many people use the start of a new year to resolve to improve their diet, get more sleep and exercise more. Professional resolutions for attorneys…
Porter Wright Morris & Arthur LLP | USA | 1 Oct 2013
When I present on e-discovery, I often use EDRM's Electronic Discovery Reference Model to explain how decisions made about the creation, storage and…
Porter Wright Morris & Arthur LLP | USA | 2 Aug 2011
On Monday, August 1, 2011, the SEC filed suit against eight defendants for making false statements in public filings regarding the status of the human clinical trials for the drug SF-1019 by Argyll Biotechnologies LLC.